Browsing by Author "Luco, Matias"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Single vs. double phototherapy in the treatment of full-term newborns with nonhemolytic hyperbilirubinemia
    (SOC BRASIL PEDIATRIA, 2009) Silva, Ignacia; Luco, Matias; Tapia, Jose L.; Eugenia Perez, Maria; Antonio Salinas, Jose; Flores, Javiera; Villaroel, Luis
    Objectives: To compare the effectiveness of single (1 panel) vs. double (2 panels) phototherapy in reducing nonhemolytic hyperbilirubinemia in term newborns.
  • Thumbnail Image
    Item
    Strategies to reduce infections and antibiotic use and its effects in a neonatal care unit
    (SOC CHILENA INFECTOLOGIA, 2017) Urzua, Soledad; Ferres, Marcela; Garcia, Patricia; Sanchez, Amparo; Luco, Matias
    Introduction: Late onset sepsis (LOS) remains an important cause of morbidity and mortality in neonatal intensive care units (NICU). The empirical use of vancomycin and other broad spectrum antibiotics is very frequent and is associated with the emergence of resistant agents, infection by gram-negative bacilli (GNB), fungal infections and increased morbidity and mortality. Objective: To evaluate the impact of 5 intervention protocols designed to reduce infections and promote the rational use of antibiotics (AB) in a single NICU. Patients and Method: Retrospective analysis included all hospitalized patients before (year 2012) and after interventions (August 2013 through July 2014). All episodes of positive cultures (blood, urine, tracheal and spinal fluid) were considered as late onset infections. Results: After intervention, a significant decrease of late onset infections was observed from 14.3 to 8.5 per 1,000 live births (p < 0.01); with a decrease in LOS from 5.7 to 2.9 per 1,000 live births, although no significant. There was a decrease in vancomycin and 3rd generation cephalosporin use without Candida spp infections in the intervention period. Mortality rates and length of hospital stay were similar in both study periods. Conclusion: After interventions, there was an important reduction in overall late onset infections and AB related costs.